Journal ArticleDOI
Disparities between prescribing of secondary prevention therapies for stroke and coronary artery disease in general practice.
Emma Heeley,Craig S. Anderson,Anushka Patel,Alan Cass,David Peiris,Andrew Weekes,John Chalmers +6 more
Reads0
Chats0
TLDR
The large treatment gap in the uptake of secondary prevention for cardiovascular disease in primary care settings is reaffirms, being much greater for patients with cerebral compared with cardiac cardiovascular disease.Abstract:
BackgroundExtensive evidence exists regarding the effectiveness of secondary prevention measures in patients with cardiovascular disease.AimWe aimed to examine the management and risk perceptions o...read more
Citations
More filters
Book ChapterDOI
Guidelines for Prevention, I
TL;DR: In most cultures, there are strong standards regarding sexual behavior which differ for men and women, and cultural differences also affect the extent to which early sexual behavior is considered acceptable.
Journal ArticleDOI
Trends in cardiovascular diseases and cancer mortality in 45 countries from five continents (1980–2010)
Fábio Araújo,Cláudia Gouvinhas,Filipa Fontes,Carlo La Vecchia,Carlo La Vecchia,Ana Azevedo,Nuno Lunet +6 more
TL;DR: The substantial decreases in CVD mortality over the last decades have overcome the impact of the growth and ageing of populations in the overall number of deaths, while stabilization in the number of cancer deaths was observed only in some of the high-income countries.
Journal ArticleDOI
Determinants for Achieving the LDL-C Target of Lipid Control for Secondary Prevention of Cardiovascular Events in Taiwan
L.-T. Ho,Wei-Hsian Yin,Shao Yuan Chuang,Wei-Kung Tseng,Yen-Wen Wu,I-Chang Hsieh,Tsung-Hsien Lin,Yi-Heng Li,Lien-Chi Huang,Kuo-Yang Wang,Kwo-Chang Ueng,Ching-Chang Fang,Wen-Harn Pan,Hung-I Yeh,Chau-Chung Wu,Jaw Wen Chen +15 more
TL;DR: Patients achieving the LDL-C target were associated with older age, more male sex, taller height, lower blood pressure, more under lipid-lowering therapy, more smoking cessation, more history of CAD, DM, physical activity, but less history of CVD.
Journal ArticleDOI
Using Patient-Reported Outcomes for Economic Evaluation: Getting the Timing Right.
TL;DR: The timing of PROM collection and the interpolation assumptions between measurements can bias economic evaluation and the design of economic evaluations should consider timing and interpolation issues.
Journal ArticleDOI
Using Classification and Regression Trees (CART) to Identify Prescribing Thresholds for Cardiovascular Disease.
TL;DR: There is little evidence that AR guidelines recommended by the National Heart Foundation and National Vascular Disease Prevention Alliance, or conditional individual risk eligibility guidelines from the Pharmaceutical Benefits Scheme, are adopted in prescribing practice.
References
More filters
Journal ArticleDOI
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients
TL;DR: Aspirin (or another oral antiplatelet drug) is protective in most types of patient at increased risk of occlusive vascular events, including those with an acute myocardial infarction or ischaemic stroke, unstable or stable angina, previous myocardian infarctions, stroke or cerebral ischaemia, peripheral arterial disease, or atrial fibrillation.
Journal ArticleDOI
Alternatives for logistic regression in cross-sectional studies: an empirical comparison of models that directly estimate the prevalence ratio
TL;DR: Cox or Poisson regression with robust variance and log-binomial regression provide correct estimates and are a better alternative for the analysis of cross-sectional studies with binary outcomes than logistic regression, since the prevalence ratio is more interpretable and easier to communicate to non-specialists than the odds ratio.
Journal ArticleDOI
Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack
Stephen MacMahon,Bruce Neal,Christophe Tzourio,Anthony Rodgers,Mark Woodward,J. Cutler,Craig S. Anderson,John Chalmers,T. Ohkubo,M. G. Bouser,Stephen M. Davis,Geoffrey A. Donnan,L. Hansson,Stephen B. Harrap,K. R. Lees,L. Liu,G. Mancia,T. Omae,J. Reid,R. Sega,A. Terent,C. Warlow,N. Anderson,C. Bladin,B.C. Chambers,G. Gordon,N. Sharpe,Rory Collins,Peter Sandercock,John Simes,P. Sleight,A. Brnabic,S. Colman,L. Francis,A. Lee,L. Gong,M.-G. Bousser,T. Yamaguchi,F. William,Q. Deng,D. X. Hu,William Y.S. Wang,A. L. Wu,L. Y. Ma,Z. Y. Tao,V. Biousse,Karine Berthet,L. Ben Slamia,C. Le Denmat,S. Crespi,G. Foglia,C. Fujimoto,S. Matsumura,K. Marttala,M. Pettersson,M. Safwenberg,J. Fenton,Y. McIlvenna,R. Currie,H. Bartram,J. Briad,A. Clague,Y. Cleverly,M. Cosson,A. Culpan,D. Douglas,S. Flett,B. Gray,T. Holloway,A. Milne,R. Prasad,Y. Ratnasabapathy,A. Santos,M. Wills,T. Agnew,Neil Chapman,N. Lewis,B. Mullane +77 more
TL;DR: This blood-pressure-lowering regimen reduced the risk of stroke among both hypertensive and non-hypertensive individuals with a history of stroke or transient ischaemic attack, irrespective of their blood pressure.
Journal ArticleDOI
Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies
TL;DR: All the classes of blood pressure lowering drugs have a similar effect in reducing CHD events and stroke for a given reduction in blood pressure, indicating that the benefit is explained by blood pressure reduction itself.
Journal ArticleDOI
Explaining the Decrease in U.S. Deaths from Coronary Disease, 1980–2000
Earl S. Ford,Umed A. Ajani,Janet B. Croft,Julia A Critchley,Darwin R. Labarthe,Thomas E. Kottke,Wayne H. Giles,Simon Capewell +7 more
TL;DR: In this paper, the authors applied a previously validated statistical model, Impact, to data on the use and effectiveness of specific cardiac treatments and on changes in risk factors between 1980 and 2000 among U.S. adults 25 to 84 years old.